We performed analysis using a public database and revealed that >70% of pathogenic or likely pathogenic variants in TP53 were registered as both somatic and germline variants, which was the highest coincidence among the 21 genes recommended by the ACMG in our tumor-only NGS panel (Fig. 2). This evidence concerns the gene TP53 and neoplasm.